Abstract
The review is devoted to the analysis of currently available non-invasive diagnostic systems for predicting the formation of fibrous changes in the liver of patients with non-alcoholic fatty liver disease. The advantages and possible limitations of each of the available diagnostic systems are analyzed.
References
1. Ахмедов В. А. Современные методы неинвазивной диагностики фиброза печени у больных неалкогольной жировой болезнью печени / В. А. Ахмедов, О. В. Гаусс // Доктор. Ру., Гастроэнтерология. – 2017. – № 2. – С. 9–12.
2. Информативность неинвазивных маркеров фиброза печени у пациентов с неалкогольной жировой болезнью печени / М. А. Ливзан, В. А. Ахмедов, Т. А. Кролевец [и др.] // Терапевтический архив. – 2016. – № 12. – С. 78–84.
3. Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic fatty liver disease / G. B. Goh, M. R. Pagadala, J. Dasarathy [et al.] // Dig. Dis. Sci. – 2015. – Vol. 60. – P. 1825–1831.
4. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? / S. McPherson, Q. M. Anstee, E. Henderson [et al.] // Eur. J. Gastroenterol. Hepatol. – 2013. – Vol. 25. – P. 652–658.
5. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection / S. G. Sheth, S. L. Flamm, F. D. Gordon [et al.] // Am. J. Gastroenterol. – 1998. – Vol. 93. – P. 44–48.
6. Calès P. Comparison of blood tests for liver fibrosis specific or not to NAFLD / P. Calès, F. Lainé, J. Boursier // J. Hepatol. – 2009. – Vol. 50. – P. 165–173.
7. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study / W. Sun, H. Cui, N. Li [et al.] // Hepatol. Res. – 2016. – Vol. 46. – P. 862–870.
8. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease / G. Ruffillo, E. Fassio, E. Alvarez [et al.] // J. Hepatol. – 2011. – Vol. 54. – P. 160–163.
9. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease / A. G. Shah, A. Lydecker, K. Murray [et al.] // Clin. Gastroenterol. Hepatol. – 2009. – Vol. 7. – P. 1104–1112.
10. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease / L. A. Adams, J. George, E. Bugianesi [et al.] // J. Gastroenterol. Hepatol. – 2011. – Vol. 26. – P. 1536–1543.
11. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease / S. A. Harrison, D. Oliver, H. L. Arnold [et al.] // Gut. – 2008. – Vol. 57. – P. 1441–1447.
12. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association / N. Chalasani, Z. Younossi, J. E. Lavine [et al.] // Hepatology. – 2012. – Vol. 55. – P. 2005–2023.
13. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease / V. Ratziu, J. Massard, F. Charlotte [et al.] // BMC Gastroenterol. – 2006. – Vol. 6. – P. 6.
14. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis / European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado // J. Hepatol. – 2015. – Vol. 63. – P. 237–264.
15. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe / Z. M. Younossi, D. Blissett, R. Blissett [et al.] // Hepatology. – 2016. – Vol. 64. – P. 1577–1586.
16. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values / R. Lichtinghagen, D. Pietsch, H. Bantel [et al.] // J. Hepatol. – 2013. – Vol. 59. – P. 236–242.
17. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease / J. Parkes, P. Roderick, S. Harris [et al.] // Gut. – 2010. – Vol. 59. – P. 1245–1251.
18. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection comparison with liver biopsy and fibrotest / A. Vallet-Pichard, V. Mallet, B. Nalpas [et al.] // Hepatology. – 2007. – Vol. 46. – P. 32–36.
19. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up / M. Ekstedt, H. Hagström, P. Nasr [et al.] // Hepatology. – 2015. – Vol. 61. – P. 1547–1554.
20. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. – 2016. – Vol. 64. – P. 73–84.
21. Guideline Development Group. Nonalcoholic fatty liver disease (NAFLD): summary of NICE guidance / J. Glen, L. Floros, C. Day [et al.] // BMJ. – 2016. – Vol. 354. – P. i4428.
22. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team / J. Dyson, B. Jaques, D. Chattopadyhay [et al.] // J. Hepatol. – 2014. – Vol. 60. – P. 110–117.
23. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis / P. Angulo, J. C. Keach, K. P. Batts [et al.] // Hepatology. – 1999. – Vol. 30. – P. 1356–1362.
24. Kaswala D. H. Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016 / D. H. Kaswala, M. Lai, N. H. Afdhal // Dig. Dis. Sci. – 2016. – Vol. 61. – P. 1356–1364.
25. Liver fibrosis in overweight patients / V. Ratziu, P. Giral, F. Charlotte [et al.] // Gastroenterology. – 2000. – Vol. 118. – P. 1117–1123.
26. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease / P. Angulo, D. E. Kleiner, S. Dam-Larsen [et al.] // Gastroenterology. – 2015. – Vol. 149. – P. 389–397.
27. The NAFLD fibrosis score: noninvasive system that identifies liver fibrosis in patients with NAFLD / P. Angulo, J. M. Hui, G. Marchesini [et al.] // Hepatology. – 2007. – Vol. 45. – P. 846–854.
28. NAFLD in Asia – as common and important as in the West / G. C. Farrell, V. W. Wong, S. Chitturi // Nat. Rev. Gastroenterol. Hepatol. – 2013. – Vol. 10. – P. 307–318.
29. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers / I. N. Guha, J. Parkes, P. Roderick [et al.] // Hepatology. – 2008. – Vol. 47. – P. 455–460.
30. A novel panel of blood markers to assess the degree of liver fibrosis / P. Calès, F. Oberti, S. Michalak [et al.] // Hepatology. – 2005. – Vol. 42. – P. 1373–1381.
31. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease / V. Nobili, J. Parkes, G. Bottazzo [et al.] // Gastroenterology. – 2009. – Vol. 136. – P. 160–167.
32. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease / M. S. Siddiqui, K. R. Patidar, S. Boyett [et al.] // Liver Int. – 2016. – Vol. 36. – P. 572–579.
33. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients / R. P. Myers, Y. Benhamou, F. Imbert-Bismut [et al.] // AIDS. – 2003. – Vol. 17. – P. 721–725.
34. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease / S. McPherson, S. F. Stewart, E. Henderson [et al.] // Gut. – 2010. – Vol. 59. – P. 1265–1269.
35. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C / C. T. Wai, J. K. Greenson, R. J. Fontana [et al.] // Hepatology. – 2003. – Vol. 38. – P. 518–526.
36. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease / H. Cichoz-Lach, K. Celinski, B. Prozorow-Król [et al.] // Med. Sci. Monit. – 2012. – Vol. 18. – P. 735–740.
37. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD) / J. Raszeja-Wyszomirska, B. Szymanik, M. Qawniczak [et al.] // BMC Gastroenterol. – 2010. – Vol. 10. – P. 67.
38. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population / Y. Sumida, M. Yoneda, H. Hyogo [et al.] // BMC Gastroenterol. – 2012. – Vol. 12. – P. 2.
2. Информативность неинвазивных маркеров фиброза печени у пациентов с неалкогольной жировой болезнью печени / М. А. Ливзан, В. А. Ахмедов, Т. А. Кролевец [и др.] // Терапевтический архив. – 2016. – № 12. – С. 78–84.
3. Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic fatty liver disease / G. B. Goh, M. R. Pagadala, J. Dasarathy [et al.] // Dig. Dis. Sci. – 2015. – Vol. 60. – P. 1825–1831.
4. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? / S. McPherson, Q. M. Anstee, E. Henderson [et al.] // Eur. J. Gastroenterol. Hepatol. – 2013. – Vol. 25. – P. 652–658.
5. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection / S. G. Sheth, S. L. Flamm, F. D. Gordon [et al.] // Am. J. Gastroenterol. – 1998. – Vol. 93. – P. 44–48.
6. Calès P. Comparison of blood tests for liver fibrosis specific or not to NAFLD / P. Calès, F. Lainé, J. Boursier // J. Hepatol. – 2009. – Vol. 50. – P. 165–173.
7. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study / W. Sun, H. Cui, N. Li [et al.] // Hepatol. Res. – 2016. – Vol. 46. – P. 862–870.
8. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease / G. Ruffillo, E. Fassio, E. Alvarez [et al.] // J. Hepatol. – 2011. – Vol. 54. – P. 160–163.
9. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease / A. G. Shah, A. Lydecker, K. Murray [et al.] // Clin. Gastroenterol. Hepatol. – 2009. – Vol. 7. – P. 1104–1112.
10. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease / L. A. Adams, J. George, E. Bugianesi [et al.] // J. Gastroenterol. Hepatol. – 2011. – Vol. 26. – P. 1536–1543.
11. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease / S. A. Harrison, D. Oliver, H. L. Arnold [et al.] // Gut. – 2008. – Vol. 57. – P. 1441–1447.
12. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association / N. Chalasani, Z. Younossi, J. E. Lavine [et al.] // Hepatology. – 2012. – Vol. 55. – P. 2005–2023.
13. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease / V. Ratziu, J. Massard, F. Charlotte [et al.] // BMC Gastroenterol. – 2006. – Vol. 6. – P. 6.
14. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis / European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado // J. Hepatol. – 2015. – Vol. 63. – P. 237–264.
15. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe / Z. M. Younossi, D. Blissett, R. Blissett [et al.] // Hepatology. – 2016. – Vol. 64. – P. 1577–1586.
16. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values / R. Lichtinghagen, D. Pietsch, H. Bantel [et al.] // J. Hepatol. – 2013. – Vol. 59. – P. 236–242.
17. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease / J. Parkes, P. Roderick, S. Harris [et al.] // Gut. – 2010. – Vol. 59. – P. 1245–1251.
18. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection comparison with liver biopsy and fibrotest / A. Vallet-Pichard, V. Mallet, B. Nalpas [et al.] // Hepatology. – 2007. – Vol. 46. – P. 32–36.
19. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up / M. Ekstedt, H. Hagström, P. Nasr [et al.] // Hepatology. – 2015. – Vol. 61. – P. 1547–1554.
20. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. – 2016. – Vol. 64. – P. 73–84.
21. Guideline Development Group. Nonalcoholic fatty liver disease (NAFLD): summary of NICE guidance / J. Glen, L. Floros, C. Day [et al.] // BMJ. – 2016. – Vol. 354. – P. i4428.
22. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team / J. Dyson, B. Jaques, D. Chattopadyhay [et al.] // J. Hepatol. – 2014. – Vol. 60. – P. 110–117.
23. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis / P. Angulo, J. C. Keach, K. P. Batts [et al.] // Hepatology. – 1999. – Vol. 30. – P. 1356–1362.
24. Kaswala D. H. Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016 / D. H. Kaswala, M. Lai, N. H. Afdhal // Dig. Dis. Sci. – 2016. – Vol. 61. – P. 1356–1364.
25. Liver fibrosis in overweight patients / V. Ratziu, P. Giral, F. Charlotte [et al.] // Gastroenterology. – 2000. – Vol. 118. – P. 1117–1123.
26. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease / P. Angulo, D. E. Kleiner, S. Dam-Larsen [et al.] // Gastroenterology. – 2015. – Vol. 149. – P. 389–397.
27. The NAFLD fibrosis score: noninvasive system that identifies liver fibrosis in patients with NAFLD / P. Angulo, J. M. Hui, G. Marchesini [et al.] // Hepatology. – 2007. – Vol. 45. – P. 846–854.
28. NAFLD in Asia – as common and important as in the West / G. C. Farrell, V. W. Wong, S. Chitturi // Nat. Rev. Gastroenterol. Hepatol. – 2013. – Vol. 10. – P. 307–318.
29. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers / I. N. Guha, J. Parkes, P. Roderick [et al.] // Hepatology. – 2008. – Vol. 47. – P. 455–460.
30. A novel panel of blood markers to assess the degree of liver fibrosis / P. Calès, F. Oberti, S. Michalak [et al.] // Hepatology. – 2005. – Vol. 42. – P. 1373–1381.
31. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease / V. Nobili, J. Parkes, G. Bottazzo [et al.] // Gastroenterology. – 2009. – Vol. 136. – P. 160–167.
32. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease / M. S. Siddiqui, K. R. Patidar, S. Boyett [et al.] // Liver Int. – 2016. – Vol. 36. – P. 572–579.
33. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients / R. P. Myers, Y. Benhamou, F. Imbert-Bismut [et al.] // AIDS. – 2003. – Vol. 17. – P. 721–725.
34. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease / S. McPherson, S. F. Stewart, E. Henderson [et al.] // Gut. – 2010. – Vol. 59. – P. 1265–1269.
35. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C / C. T. Wai, J. K. Greenson, R. J. Fontana [et al.] // Hepatology. – 2003. – Vol. 38. – P. 518–526.
36. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease / H. Cichoz-Lach, K. Celinski, B. Prozorow-Król [et al.] // Med. Sci. Monit. – 2012. – Vol. 18. – P. 735–740.
37. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD) / J. Raszeja-Wyszomirska, B. Szymanik, M. Qawniczak [et al.] // BMC Gastroenterol. – 2010. – Vol. 10. – P. 67.
38. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population / Y. Sumida, M. Yoneda, H. Hyogo [et al.] // BMC Gastroenterol. – 2012. – Vol. 12. – P. 2.